Molecular Insight Pharmaceuticals, Inc. to Present Clinical, Preclinical Data at the Society of Nuclear Medicine 2009

CAMBRIDGE, MA, Jun 10 (MARKET WIRE) --
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) researchers will
present data on the Company's progress in developing novel
radiopharmaceuticals that may provide a promising option for molecular
imaging of solid tumors, at the Society of Nuclear Medicine (SNM) annual
meeting in Toronto. The presentations include clinical data on Molecular
Insight's Trofex(TM), a radiolabeled, small-molecule molecular imaging
pharmaceutical in development for diagnosis and staging of prostate
cancer. Trofex, an internally developed compound, targets prostate
specific membrane antigen (PSMA), a protein highly expressed by prostate
tumor cells, and has the potential to both detect and, when labeled with a
therapeutic isotope, treat metastatic prostate cancer. Data also will be
presented on Molecular Insight's recent discovery research oncology
projects that have focused on the development of radiolabeled
small-molecule inhibitors that target the cancer-related enzymes, carbonic
anhydrase IX and seprase.

Clinical Data
Oral Presentation: J.A. Barrett
Tuesday, June 16, 3:30 PM, Room 705
Abstract # 522
Abstract Title: Targeting Metastatic Prostate Cancer (PCa) in Patients
using 123I-MIP 1072 & 123I-MIP 1095
Authors: J.A. Barrett(1); N.D. LaFrance(1); R.E. Coleman(2);
S.J. Goldsmith(3); J.B. Stubbs(4); N. Petry(2);
S. Vallabhajosula(3); K.P. Maresca(1); F. Femia(1);
M. Stabin(4); J.W. Babich(1)
(1)Molecular Insight Pharmaceuticals, Inc., Cambridge, MA,
(2)Duke University, Durham, NC,
(3)Cornell Medical Center, NY, NY,
(4)Radiation Dosimetry Systems, Inc., Palo Alto, CA

Preclinical Data
Oral Presentation: K.P. Maresca
Monday, June 15, 10:24 AM, Room 713B
Abstract # 146
Abstract Title: Molecular Targeting using Advanced Single Amino Acid
Chelates (SAAC) for 99mTc
Authors: K.P. Maresca; S.M. Hillier; G. Lu; J.C. Marquis;
C.N. Zimmerman; W.C. Eckelman; J.L. Joyal; J.W. Babich
All: Molecular Insight Pharmaceuticals, Cambridge, MA

Poster Presentation
Tuesday, June 16, 4:30 PM, Exhibit Hall E/F
Abstract # 1561
Abstract Title: Small Molecule Carbonic Anhydrase IX Inhibitors for
Targeted Molecular Imaging of Cancer by SPECT
Authors: S.M. Hillier; G. Lu; C. Shay; K.P. Maresca;
C. Barone; J.C. Marquis; C.N. Zimmerman;
W.C. Eckelman; J.L. Joyal; J.W. Babich
All: Molecular Insight Pharmaceuticals, Cambridge, MA

Poster Presentation
Tuesday, June 16, 4:30 PM, Exhibit Hall E/F
Abstract # 1563
Abstract Title: Radiolabeled Inhibitors of Seprase Targeting the
Tumor Microenvironment
Authors: J.C. Marquis; J.C. Wang; K.P. Maresca; S.M. Hillier;
C.N. Zimmerman; W.C. Eckelman; J.L. Joyal; J.W. Babich
All: Molecular Insight Pharmaceuticals, Inc., Cambridge, MA

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a Cambridge,
Massachusetts-based biopharmaceutical company focused on the discovery and
development of innovative radiopharmaceuticals in the emerging field of
molecular medicine. These novel radiopharmaceuticals will provide
important improvements in disease detection and enable the delivery of
radiation therapy to widespread metastatic cancers. The Company has
focused the initial applications of its proprietary technologies in the
areas of cardiology and oncology. Molecular Insight's lead molecular
imaging radiopharmaceutical product candidate, Zemiva(TM), is being
developed for the diagnosis of cardiac ischemia, or insufficient blood
flow to the heart. The Company's imaging candidate, Trofex(TM), is in
development for the detection of metastatic prostate cancer. Molecular
Insight's lead molecular radiotherapeutic product candidates, Azedra(TM),
Onalta(TM), and Solazed(TM), are being developed for detection and
treatment of cancer. In addition, the Company's discovery efforts continue
to identify early-stage candidates -- a product of its in-house scientific
expertise and the application of its proprietary platform technologies.
For more information, visit http://www.molecularinsight.com.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature
constitute "forward-looking statements." Such statements include, but are
not limited to, statements about the development of Zemiva(TM), Trofex(TM)
, Azedra(TM), Onalta(TM), Solazed(TM), and the Company's other product
candidates. Such forward-looking statements involve known and unknown
risks, uncertainties, and other factors that may cause the actual results
of Molecular Insight to be materially different from historical results or
from any results expressed or implied by such forward-looking statements.
These factors include, but are not limited to, risks and uncertainties
related to the progress, timing, cost, and results of clinical trials and
product development programs; difficulties or delays in obtaining
regulatory approval for product candidates; competition from other
pharmaceutical or biotechnology companies; and the additional risks
discussed in filings with the Securities and Exchange Commission (SEC).
The Company's SEC filings are available through the SEC's Electronic Data
Gathering Analysis and Retrieval system (EDGAR) at http://www.sec.gov.
Press releases for Molecular Insight Pharmaceuticals, Inc. are available
on our website: http://www.molecularinsight.com. If you would like to
receive press releases via e-mail, please contact:
investor@molecularinsight.com. All forward-looking statements are
qualified in their entirety by this cautionary statement, and Molecular
Insight undertakes no obligation to revise or update this release to
reflect events or circumstances after the date hereof.

Contact:
Deborah S. Lorenz
Senior Director
Investor Relations and Corporate Communications
Molecular Insight Pharmaceuticals, Inc.
(617) 871-6667
dlorenz@molecularinsight.com

Copyright 2009, Market Wire, All rights reserved.

-0-